Mateos, María-Victoria http://orcid.org/0000-0003-2390-1218
Kumar, Shaji http://orcid.org/0000-0001-5392-9284
Dimopoulos, Meletios A. http://orcid.org/0000-0001-8990-3254
González-Calle, Verónica
Kastritis, Efstathios
Hajek, Roman
De Larrea, Carlos Fernández
Morgan, Gareth J.
Merlini, Giampaolo http://orcid.org/0000-0001-7680-3254
Goldschmidt, Hartmut http://orcid.org/0000-0003-0961-0035
Geraldes, Catarina
Gozzetti, Alessandro http://orcid.org/0000-0003-0769-6891
Kyriakou, Charalampia
Garderet, Laurent
Hansson, Markus http://orcid.org/0000-0002-7715-4548
Zamagni, Elena
Fantl, Dorotea
Leleu, Xavier
Kim, Byung-Su
Esteves, Graça
Ludwig, Heinz
Usmani, Saad http://orcid.org/0000-0002-5484-8731
Min, Chang-Ki
Qi, Ming
Ukropec, Jon
Weiss, Brendan M.
Rajkumar, S. Vincent http://orcid.org/0000-0002-5862-1833
Durie, Brian G. M.
San-Miguel, Jesús http://orcid.org/0000-0002-9183-4857
Funding for this research was provided by:
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Article History
Received: 8 June 2020
Revised: 16 September 2020
Accepted: 22 September 2020
First Online: 16 October 2020
Conflict of interest
: M.-V.M. reports grants from Janssen, Celgene, Amgen, Takeda, Abbvie, GSK, Adaptive, EDO Mundipharma, Pharmamar, Roche, Seattle Genetics, outside the submitted work; S.K. reports research funding for clinical trials to the institution: Celgene, Takeda, Janssen, BMS, KITE, Merck, AbbVie, Medimmune, Novartis, Roche-Genentech, Amgen, Tenebio, Carsgen; and Consulting/Advisory Board participation: (with no personal payments) Celgene, Takeda, Janssen, AbbVie, Genentech, Amgen, Molecular Partners and (with personal payment) Oncopeptides, Gene Centrix, Cellectar. M.A.D. reports personal fees from Amgen, Celgene, Takeda, Janssen, and BMS, outside the submitted work. V.G.-C. reports grants from Janssen, personal fees from Advisory Board of Prothena, non-financial support from Janssen and Celgene, outside the submitted work; E.K. reports grants and personal fees from Amgen, personal fees and non-financial support from Genesis Pharma, grants, personal fees, and non-financial support from Janssen, personal fees from Takeda and Pfizer, during the conduct of the study; R.H. has nothing to disclose. C.F.d.L. reports grants, personal fees, and non-financial support from Janssen, Celgene, Takeda, and Amgen, outside the submitted work; G.J.M.: Advisory Boards from Celgene, BMS, Sanofi, Karyopharm, Janssen, Roche, and Genentech. G.M. has nothing to disclose. H.G. reports grants, personal fees and other fees from Celgene, Janssen, BMS, and Sanofi, grants and other from Chugai, grants from John Hopkins University and Dietmar Hopp Stiftung, other fees from Amgen, Molecular Partners, MSD, Mundipharma, and Art Tempi, personal fees and other fees from Takeda and Novartis, non-financial support and other fees from Adaptive Biotechnology, outside the submitted work. C.G. has nothing to disclose. A.G. reports grants and personal fees from Janssen, personal fees from Celgene, Amgen, and Takeda, outside the submitted work; C.K. has nothing to disclose. L.G. has nothing to disclose. M.H. has nothing to disclose. E.Z.: Advisory Board for Sanofi, BMS, Janssen, and Takeda. D.F. reports personal fees from Amgen, Janssen, Varifarma, Tecnofarma, Takeda, Sanofi, Glaxo, and Bristol Myers, outside the submitted work; X.L. has nothing to disclose. B.-S.K. reports grants from National Research Foundation of Korea (NRF), during the conduct of the study; G.E. has nothing to disclose. H.L. reports grants from Amgen, Takeda, personal fees from Amgen, Takeda, Janssen, BMS, Celgene, Seattle Genetics, and Sanofi, outside the submitted work; S.U. reports grants and personal fees from Amgen, Celgene, Sanofi, Seattle Genetics, Janssen, Takeda, SkylineDX, and Merck, personal fees from Abbvie and MundiPharma, grants from BMS and Pharmacyclics, outside the submitted work; C.-K.M. has nothing to disclose. M.Q.: employment from Janssen Research and Development; stock or other ownership from Janssen Research and Development. J.U.: employment from Janssen; stock or other ownership from Janssen. B.M.W. is an employee of Janssen Research & Development. S.V.R. has nothing to disclose. B.G.M.D.: Advisory Board for Amgen, Janssen, Celgene/BMS, and Takeda. J.S.-M. reports other fees from Amgen, BMS, Celgene, Janssen, MSD, Novartis, Takeda, Sanofi, Roche, GSK, AbbVie, and Karyopharm, outside the submitted work.